Amoytop Biotech's Yipei growth hormone injection approved for launch

Xiamen Amoytop Biotech announced that its Yipei (怡培) growth hormone injection has received approval from the National Medical Products Administration and will soon be available on the market. The drug is indicated for growth retardation caused by growth hormone deficiency in children aged 3 years and older. Yipei is a long-acting recombinant human growth hormone using 40kD Y-type branched polyethylene glycol (PEG) for single-molecule modification. This formulation allows for weekly administration instead of daily injections, aiming to improve patient compliance and reduce the burden of treatment. Amoytop Biotech anticipates that the launch of Yipei will strengthen its product portfolio and contribute positively to its future financial performance. The company advises investors to be aware of market uncertainties in the pharmaceutical industry.